William Richard White Sells 1,634 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 1,634 shares of the firm’s stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $54.84, for a total transaction of $89,608.56. Following the completion of the sale, the chief financial officer now directly owns 57,521 shares of the company’s stock, valued at approximately $3,154,451.64. The trade was a 2.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

William Richard White also recently made the following trade(s):

• On Tuesday, June 10th, William Richard White sold 2,804 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.99, for a total transaction of $151,387.96.

Akero Therapeutics Stock Performance

Shares of NASDAQ:AKRO opened at $54.20 on Friday. The company has a market capitalization of $4.32 billion, a price-to-earnings ratio of -27.79 and a beta of -0.16. Akero Therapeutics, Inc. has a 52 week low of $21.02 and a 52 week high of $58.40. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03. The firm has a 50 day moving average of $45.88 and a 200 day moving average of $41.17.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of ($1.01) by $1.91. On average, sell-side analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AKRO. RTW Investments LP grew its holdings in Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock worth $190,840,000 after purchasing an additional 940,388 shares during the last quarter. Deep Track Capital LP grew its holdings in Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company’s stock worth $41,452,000 after purchasing an additional 800,216 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Akero Therapeutics in the fourth quarter worth $18,059,000. SG Americas Securities LLC grew its holdings in Akero Therapeutics by 93.3% in the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company’s stock worth $46,786,000 after purchasing an additional 557,794 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new position in Akero Therapeutics in the first quarter worth $21,333,000.

Analyst Ratings Changes

AKRO has been the subject of several research analyst reports. Morgan Stanley reaffirmed an “overweight” rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Citigroup decreased their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Bank of America lifted their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a “buy” rating in a research note on Tuesday, May 27th. Finally, HC Wainwright boosted their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Monday, March 3rd. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.